Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial Publisher Pubmed



Abbasi SH1, 2 ; Mohammadinejad P3 ; Shahmansouri N1 ; Salehiomran A1 ; Beglar AA1 ; Zeinoddini A3 ; Forghani S4 ; Akhondzadeh S3
Authors

Source: Journal of Affective Disorders Published:2015


Abstract

Abstract Background A decreased risk of developing depression has been reported among statin users. Aside from their lipid-lowering effects, statins are considered immunomodulatory agents and have protective effects against oxidative stress and inflammation which are well known for their association with depression. The aim of the present study was to compare the probable antidepressant effects of simvastatin and atorvastatin among post-coronary artery bypass graft (CABG) surgery patients with high and low potentials for blood-brain-barrier penetration, respectively. Method Forty-six outpatients who had undergone CABG in the last 6 months and suffered from mild to moderate depression participated in a parallel, double-blind, placebo-controlled trial, and were randomized to undergo 6 weeks of treatment with either simvastatin (20 mg/day) or atorvastatin (20 mg/day). Participants were evaluated using Hamilton depression rating scale (HDRS) at baseline and weeks 3 and 6. The primary outcome was to evaluate the efficacy of simvastatin in improving the depressive symptoms. Result General linear model repeated measures demonstrated significant effect for time×treatment interaction on the HDRS scores [F (1.62, 71.06)=3.41, P=0.048]. There was no significant difference between the treatment groups regarding the adverse events. No one experienced serious adverse event. Limitation The limitations of the present study were its small sample size and the short-term follow-up period. Conclusion Treatment with simvastatin seems to be well tolerated with superior antidepressant effects compared to atorvastatin in post-CABG patients. Long-term outcomes of this practice and its probable influence on other psychological aspects are yet to be investigated in future studies. Trial registration Iranian registry of clinical trials (http://www.irct.ir): IRCT201410271556N68. © 2015 Elsevier B.V.
Other Related Docs
11. Monoclonal Antibody a Promising Treatment for Depression, Avicenna Journal of Medical Biotechnology (2019)
19. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)